Vir Biotechnology (VIR) Short term Debt (2019 - 2025)

Vir Biotechnology's Short term Debt history runs 5 years deep, the most recent figure standing at $17.5 million for Q1 2025.

• In Q1 2025, Short term Debt changed N/A year-over-year to $17.5 million; the TTM figure through Mar 2025 stood at $17.5 million (changed N/A YoY), while the FY2024 annual figure was $16.1 million, changed N/A from the prior year.
• Short term Debt came in at $17.5 million for Q1 2025 at Vir Biotechnology, up from $16.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $68.5 million in Q3 2021 to a low of $16.1 million in Q4 2024.
• A 3-year average of $30.5 million and a median of $24.4 million in 2021 frame the typical range for Short term Debt.
• On a YoY basis, Short term Debt climbed as much as 457.45% in 2021 and fell as far as 128.04% in 2021.
• Vir Biotechnology's Short term Debt stood at $68.5 million in 2021, then sank by 76.55% to $16.1 million in 2024, then increased by 8.97% to $17.5 million in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $17.5 million, $16.1 million, and $68.5 million for Q1 2025, Q4 2024, and Q3 2021 respectively.

Peer Comparison